Get the Stockscreener App
10.01
2.05%
-0.21
After Hours:
10.01
Beta Bionics Inc stock is traded at $10.01, with a volume of 319.45K.
It is down -2.05% in the last 24 hours and up +0.81% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
See More
Previous Close:
$10.22
Open:
$10.24
24h Volume:
319.45K
Relative Volume:
0.28
Market Cap:
$446.06M
Revenue:
$110.24M
Net Income/Loss:
$-66.44M
P/E Ratio:
-6.6243
EPS:
-1.5111
Net Cash Flow:
$-61.12M
1W Performance:
-0.69%
1M Performance:
+0.81%
6M Performance:
-62.24%
1Y Performance:
-14.30%
1-Day Range:
$9.89
$10.31
1-Week Range:
$9.59
$10.54
52-Week Range:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
10.01 | 455.42M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | UBS | Buy |
| Jan-27-26 | Initiated | TD Cowen | Hold |
| Jan-09-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-21-25 | Resumed | Stifel | Buy |
| Oct-01-25 | Upgrade | Goldman | Neutral → Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock? - MSN
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99 - MSN
Midday Stock Roundup: Tech stocks rally - Orange County Business Journal
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates - MSN
Beta Bionics to Present at the Bank of America Securities Health Care Conference - marketscreener.com
Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% - MSN
BBNX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
BBNX (Beta Bionics Inc.) posts narrower Q4 2025 loss than consensus estimates, sending shares up more than six percent.Analyst Recommended Stocks - Xã Thanh Hà
Beta Bionics Earnings Call Highlights Growth And Risks - The Globe and Mail
Piper Sandler cuts Beta Bionics stock price target on valuation - Investing.com UK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Beta Bionics, Inc. (BBNX) and Danaher (DHR) - The Globe and Mail
BBNX Beta Bionics posts narrower Q4 2025 loss than analyst estimates, strong year over year revenue growth lifts shares slightly.Verified Stock Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Piper Sandler cuts Beta Bionics stock price target on valuation By Investing.com - Investing.com India
Wolfe Research cuts Beta Bionics stock price target on guidance By Investing.com - Investing.com India
Beta Bionics, Inc. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Risk Factors - Minichart
Beta Bionics Raises Outlook on 57% Q1 Revenue Growth - Orange County Business Journal
Lake Street reiterates Buy on Beta Bionics stock on Q1 beat - Investing.com UK
Lake Street reiterates Buy on Beta Bionics stock on Q1 beat By Investing.com - Investing.com South Africa
Beta Bionics (NASDAQ:BBNX) Price Target Cut to $24.00 by Analysts at Leerink Partners - MarketBeat
Beta Bionics (NASDAQ:BBNX) Shares Gap Up on Strong Earnings - MarketBeat
BofA cuts Beta Bionics stock price target on patient start outlook - Investing.com UK
Beta Bionics (NASDAQ:BBNX) Given New $20.00 Price Target at Stifel Nicolaus - MarketBeat
BofA cuts Beta Bionics stock price target on patient start outlook By Investing.com - Investing.com South Africa
Stifel cuts Beta Bionics stock price target on opex ramp concerns - Investing.com Australia
Beta Bionics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Stifel cuts Beta Bionics stock price target on opex ramp concerns By Investing.com - Investing.com South Africa
Wolfe Research cuts Beta Bionics stock price target on guidance - Investing.com UK
Beta Bionics Inc Stock (BBNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):